Key result
DOACs cost up to ~$500 monthly out-of-pocket, posing major affordability barriers for under-resourced patients.
Why the study?
Little is known about direct oral anticoagulant use among socioeconomically disadvantaged populations who may face prohibitive out-of-pocket costs.
Key points are not available for this paper at this time.
Design
Characterization study
The direct oral anticoagulants (DOAC) are safer and easier to use than warfarin. Little is known about DOAC use among socioeconomically disadvantaged populations, for whom DOAC cost (out-of-pocket cost of $387 to $525 for a 1-month supply) [(1)][1] may be prohibitive. We characterized DOAC use
No takes yet. Share an insight, caveat, or question.
Ting et al. (2019) studied this question. Direct oral anticoagulants have an out-of-pocket cost of $387 to $525 for a 1-month supply, which may be prohibitive for patients with limited income and resources.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: